pdf string | doi string | doi_sourse string | supplementary int64 | title string | publisher string | year int64 | access int64 | compound_id string | compound_name string | SMILES string | SMILES_type string | metal string | target string | page_smiles int64 | origin_smiles string | page_metal int64 | origin_metal string | page_target_value float64 | origin_target_value string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | Tetrofosmin | CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC.[O-2].[O-2] | environment | Tc | null | 4 | figure 3 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | HMPAO | CC(=N[O-])C(C)[N-]CC(C)(C)C[N-]C(C)C(C)=NO.[O-2] | environment | Tc | null | 4 | figure 3 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | ECD | CCOC(=O)C([N-]CCNC(C(=O)OCC)C(C)(C)[S-])C(C)(C)[S-].[O-2] | environment | Tc | null | 4 | figure 3 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | MAG3 | O=C(O)C[N-]C(=O)C[N-]C(=O)C[N-]C(=O)C[S-].[O-2] | environment | Tc | null | 4 | figure 3 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | TRODAT-1 | CN1C2CCC1C(CN(CC[S-])CC[N-]CC[S-])C(c1ccc(Cl)cc1)C2.[O-2] | environment | Tc | null | 5 | figure 4 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | Tektrotyd | C=C1NC(C(C)O)C(=O)NC(C(=C)NC(CO)C(C)O)CSSCC(NC(=O)C(NC(=O)c2ccc(N=[N-])nc2)c2ccccc2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC1CCCCN.O=C([O-])C[N-]CC[N-]CC(=O)[O-] | environment | Tc | null | 5 | figure 4 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | DADT | [O-2].[S-]CC[N-]CCNCC[S-] | environment | Tc | null | 6 | figure 7 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | MAMA | O=C(CNCC[S-])[N-]CC[S-].[O-2] | environment | Tc | null | 6 | figure 7 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | DADS | O=C(C[S-])[N-]CC[N-]C(=O)C[S-].[O-2] | environment | Tc | null | 6 | figure 7 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | (acac)2en | CC([O-])=CC(C)=NCCN=C(C)C=C(C)[O-].[O-2].[O] | environment | Tc | null | 6 | figure 9 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | furifosmin | CC1(C)OC(C)(C)C(C=NCCN=CC2=C([O-])C(C)(C)OC2(C)C)=C1[O-].COCCCP(CCCOC)CCCOC.COCCCP(CCCOC)CCCOC | environment | Tc | null | 6 | figure 9 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | CC1(C[S-])[N-]CCC1O.CN1CCC(=O)CC1C[S-].[O-2] | environment | Tc | null | 6 | figure 10 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | glucoheptate | O=C([O-])C([O-])C(O)C(O)C(O)C(O)CO.O=C([O-])C([O-])C(O)C(O)C(O)C(O)CO.[O-2] | environment | Tc | null | 7 | figure 11 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | endo-DMSA | O=C(O)C([S-])C([S-])C(=O)O.O=C(O)C([S-])C([S-])C(=O)O.[O-2] | environment | Tc | null | 7 | figure 11 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | exo-DMSA | O=C(O)C([S-])C([S-])C(=O)O.O=C(O)C([S-])C([S-])C(=O)O.[O-2] | environment | Tc | null | 7 | figure 11 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | anti-DMSA | O=C(O)C([S-])C([S-])C(=O)O.O=C(O)C([S-])C([S-])C(=O)O.[O-2] | environment | Tc | null | 7 | figure 11 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | tetramine | NCCNCCCNCCN.[O-2].[O-2] | environment | Tc | null | 7 | figure 12 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | OCP(CO)CCSCCCSCCP(CO)CO.[O-2].[O-2] | environment | Tc | null | 7 | figure 12 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | OCP(CO)CCNCCCNCCP(CO)CO.[O-2].[O-2] | environment | Tc | null | 7 | figure 12 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | NOET | CCON(CC)C(=S)[S-].CCON(CC)C(=S)[S-].[N-3] | environment | Tc | null | 7 | figure 13 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | (HYNIC)(tricine)2 | O=C([O-])C[N-]C(CO)(CO)CO.O=C([O-])C[N-]C(C[O-])(CO)CO.[N-]=Nc1ccc(C(=O)O)cn1 | environment | Tc | null | 8 | figure 14 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | (HYNIC)(EDDA) | O=C([O-])CNCCNCC(=O)[O-].[N-]=Nc1ccc(C(=O)O)cn1 | environment | Tc | null | 8 | figure 14 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | (HYNIC)2(SNS) | CN(CC[S-])CC[S-].[N-]=Nc1ccc(C(=O)O)cn1.[N-]=Nc1ccc(C(=O)O)cn1 | environment | Tc | null | 8 | figure 14 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | 2 | null | NC(Cc1c[nH]cn1)C(=O)[O-].[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 9 | figure 16 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | 2 | null | NC(Cc1c[nH]nn1)C(=O)[O-].[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 9 | figure 16 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | 6 | null | O=C([O-])c1ccccn1.[C-]#[O+].[C-]#[O+].[C-]#[O+].c1c[nH]cn1 | environment | Tc | null | 9 | figure 16 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cn(CCNCCn2ccnc2)cn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cn(CCNCCn2ccnn2)nn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cnn(CCNCCn2cccn2)c1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cc[n+](CCNCC[n+]2ccccc2)cc1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | NCCNCCN | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cn(CCSCCn2ccnc2)cn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cn(CCSCCn2ccnn2)nn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cnn(CCSCCn2cccn2)c1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | c1cc[n+](CCSCC[n+]2ccccc2)cc1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | NCCSCCN | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CNCCn1ccnc1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CNCCn1ccnn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CNCCn1cccn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CNCC[n+]1ccccc1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | NCCNCC(=O)O | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CSCCn1ccnc1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CSCCn1ccnn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CSCCn1cccn1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)CSCC[n+]1ccccc1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | NCCSCC(=O)O | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | null | O=C(O)C1=CC2C3CC(C=C3C(=O)O)C2C1 | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | TMEOP | COCc1nn(C(n2nc(COC)c(COC)c2COC)n2nc(COC)c(COC)c2COC)c(COC)c1COC | ligand | Tc | null | 9 | figure 17 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | depreotide | CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(Cc2ccccc2)N(C)C(=O)C(CCSCC(=O)NCC(N)C(=O)[N-]C(CCCCN)C(=O)[N-]C(C[S-])C(=O)CC(CCCCN)C(N)=O)NC1=O.[O-2] | environment | Tc | null | 11 | figure 19 | 1 | title | null | null |
papagiannopoulou2017 | 10.1002/jlcr.3531 | 10.1002/jlcr.3531 | 0 | Technetium‐99m radiochemistry for pharmaceutical applications | Wiley | 2,017 | 0 | null | MIP-1404 | O=C(O)CCC(NC(=O)NC(CCC(=O)NC(CCCCN(Cc1nccn1CC(=O)N(CC(=O)O)CC(=O)O)Cc1nccn1CC(=O)N(CC(=O)O)CC(=O)O)C(=O)O)C(=O)O)C(=O)O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 11 | figure 19 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | MIBI | [C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC | environment | Tc | null | 2 | figure 1 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | Q12 | CC1(C)OC(C)(C)C(C=NCCN=CC2=C([O-])C(C)(C)OC2(C)C)=C1[O-].COCCCP(CCCOC)CCCOC.COCCCP(CCCOC)CCCOC | environment | Tc | null | 2 | figure 1 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | P53 | CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC.[O-2].[O-2] | environment | Tc | null | 2 | figure 1 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR1)2 | CCC[S-].CCC[S-].C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR2)2 | COCC[S-].COCC[S-].C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR3)2 | COCC(C[S-])OC.COCC(C[S-])OC.C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR4)2 | CC1(C)OCC(C[S-])O1.CC1(C)OCC(C[S-])O1.C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR5)2 | C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C.[S-]CCC1OCCCO1.[S-]CCC1OCCCO1 | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR6)2 | COCC(CCC[S-])COC.COCC(CCC[S-])COC.C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
tisato1996 | 10.1021/jm9507789 | 10.1021/jm9507789 | 0 | Cationic [<sup>99m</sup>Tc<sup>III</sup>(DIARS)<sub>2</sub>(SR)<sub>2</sub>]<sup>+</sup> Complexes as Potential Myocardial Perfusion Imaging Agents (DIARS = <i>o</i>-phenylenebis(dimethylarsine); SR<sup>-</sup> = thiolate) | American Chemical Society (ACS) | 1,996 | 0 | null | (DIARS)2(SR7)2 | C[As](C)c1ccccc1[As](C)C.C[As](C)c1ccccc1[As](C)C.OCC[S-].OCC[S-] | environment | Tc | null | 2 | figure 1, 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | 2a | null | C=C(C[S-])[N-]CC(=O)[N-]CC(=O)[N-]CC(=O)[O-].[Na+].[Na+].[O-2] | environment | Tc | null | 3 | figure 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | 2b | null | CC(=N[O-])C(C)[N-]CC(C)(C)C[N-]C(C)C(C)=NO.[O-2] | environment | Tc | null | 3 | figure 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | 2c | null | CCOC(=O)C(C[S-])[N-]CCNC(C[S-])C(=O)OCC.[O-2] | environment | Tc | null | 3 | figure 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | 2d | null | CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC.[O-2].[O-2] | environment | Tc | null | 3 | figure 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | 2e | null | CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC.[O-2].[O-2] | environment | Tc | null | 3 | figure 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | 2f | null | [C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC | environment | Tc | null | 3 | figure 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C1 | null | CC(=C(c1ccc(O)cc1)c1ccc(OCC(=O)[c-]2cccc2)cc1)c1ccc(O)cc1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 6 | scheme 1 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C3a | null | CC(C)CC(NC(=O)[c-]1cccc1)C(=O)NCC(=O)NCC(=O)O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 7 | scheme 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C3b | null | O=C(CNC(=O)C(CC1=CCC2=C1C=CCC=C2)NC(=O)[c-]1cccc1)NC(Cc1ccc(O)cc1)C(=O)O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 7 | scheme 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C3c | null | CC(C)CC(NC(=O)[c-]1cccc1)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 7 | scheme 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C3d | null | CSCCC(NC(=O)C(CCSC)NC(=O)C(CCSC)NC(=O)[c-]1cccc1)C(=O)O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 7 | scheme 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C3e | null | CC(C)CC(NC(=O)C(C)NC(=O)C(NC(=O)[c-]1cccc1)C(C)C)C(=O)O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 7 | scheme 2 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C4-R2 | null | COc1ccccc1N1CCN(CCCNC(=O)c2cc[cH-]c2)CC1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 8 | scheme 3 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C4-R3 | null | O=C(c1cc[cH-]c1)N1CCN(c2ccccc2)CC1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 8 | scheme 3 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C5a | null | COc1ccc([P+](CCCCCC(=O)[c-]2cccc2)(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 8 | scheme 3 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C5b | null | COc1cccc(OC)c1[P+](CCCCCC(=O)[c-]1cccc1)(c1c(OC)cccc1OC)c1c(OC)cccc1OC.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 8 | scheme 3 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C7 | null | O=C(Nc1ccccc1)[c-]1cccc1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 9 | scheme 4 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C8 | null | C[B-](ON=C1CCCCC1=N[O-])(ON=C1CCCCC1=NO)ON=C1CCCCC1=NO.[Cl-] | environment | Tc | null | 10 | scheme 5 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C10 | null | Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O | environment | Tc | null | 11 | scheme 6 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C11a | MIPrDP | Cc1nccn1CCC(O)(P(=O)([O-])O)P(=O)([O-])O.Cc1nccn1CCC(O)(P(=O)([O-])O)P(=O)([O-])O | environment | Tc | null | 11 | scheme 6 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C11b | MIBDP | Cc1nccn1CCCC(O)(P(=O)([O-])O)P(=O)([O-])O.Cc1nccn1CCCC(O)(P(=O)([O-])O)P(=O)([O-])O | environment | Tc | null | 11 | scheme 6 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C11c | MIPeDP | Cc1nccn1CCCCC(O)(P(=O)([O-])O)P(=O)([O-])O.Cc1nccn1CCCCC(O)(P(=O)([O-])O)P(=O)([O-])O | environment | Tc | null | 11 | scheme 6 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C12 | null | CCCCC[N+](CCCC)(CCCC)CCCC.Cl.O=C(C=C([O-])C(F)(F)F)C(F)(F)F.[Cl-].[Cl-] | environment | Tc | null | 11 | scheme 6 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C13 | null | C[N+]12CN3CN(CP(C3)C1)C2.C[N+]12CN3CN(CP(C3)C1)C2.[Cl-].[Cl-].[Cl-].[Cl-] | environment | Tc | null | 12 | scheme 7 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C14 | null | CN1[C]N(C)C=C1.CN1[C]N(C)C=C1.CN1[C]N(C)C=C1.CN1[C]N(C)C=C1.[O-2] | environment | Tc | null | 12 | scheme 8 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C15 | null | CC(COC(=O)C(C)(COC(=O)C(C)(COC(=O)C(C)(COC(=O)C(C)(CO)CO)COC(=O)C(C)(CO)CO)COC(=O)C(C)(COC(=O)C(C)(CO)CO)COC(=O)C(C)(CO)CO)COC(=O)C(C)(COC(=O)C(C)(COC(=O)C(C)(CO)CO)COC(=O)C(C)(CO)CO)COC(=O)C(C)(COC(=O)C(C)(CO)CO)COC(=O)C(C)(CO)CO)(COC(=O)C(C)(COC(=O)C(C)(COC(=O)C(C)(COC(=O)C(C)(CO)CO)COC(=O)C(C)(CO)CO)COC(=O)C(C)(COC(... | environment | Tc | null | 13 | scheme 9 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C16 | null | O=C(O)CCc1ccc(C(=O)CCCCCCCCCCCN(Cc2ccccn2)Cc2ccccn2)s1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 13 | scheme 10 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C17 | null | CC1N=CC([N+](=O)[O-])=[N+]1CCC1C=C(CCN(Cc2ccccn2)Cc2ccccn2)N=N1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 13 | scheme 10 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C18 | null | O=C(O)CCCCN(Cc1nccs1)Cc1nccs1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 15 | scheme 11 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C19 | null | CC(=O)C1CCCCNC(=O)C(Cc2ccc(O)cc2)NC(=O)C(C)NC(=O)C[N]Cc2cccc(n2)C[N]CC(=O)NC(C)C(=O)NC(Cc2ccc(O)cc2)C(=O)N1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 15 | scheme 11 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C20 | null | CC1=CN(C2CC(O)C(CO)O2)C(C)N(Cn2cc(CN3CCCNCCCNCCC3)nn2)C1=O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 16 | scheme 12 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C21 | null | CN1C=C[N-]C1.O=S(=O)(O)c1ccc(-c2ccnc3c2ccc2c(-c4ccc(S(=O)(=O)O)cc4)ccnc23)cc1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 16 | scheme 12 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C22 | null | O=C(CCCCN1C=C[N-]C1)NCCCC(P(=O)(O)O)(P(=O)(O)O)P(=O)(O)O.O=S(=O)(O)c1ccc(-c2ccnc3c2ccc2c(-c4ccc(S(=O)(=O)O)cc4)ccnc23)cc1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 16 | scheme 12 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C23 | null | Cc1cc(C)n(CCN(CCN)CCCNC(=O)C(N)CCCNC(=N)N)n1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 17 | scheme 13 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C24 | null | Cc1cc(C)n(CCN(CCN)CCCCCCNC(=O)C(N)CCCNC(=N)N)n1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 17 | scheme 13 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C25 | null | CCCCC(=O)NCc1ccc(-c2nncnn2)cc1.[C-]#[O+].[C-]#[O+].[C-]#[O+].c1ccc(-c2ccccn2)nc1 | environment | Tc | null | 18 | scheme 14 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C26 | null | CCCCC(=O)NCc1ccc(-c2nncnn2)cc1.O=S(=O)([O-])c1ccc(-c2ccnc3c2ccc2c(-c4ccc(S(=O)(=O)[O-])cc4)ccnc23)cc1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 18 | scheme 14 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C27 | null | COc1ccccc1N1CCN(CCC[n+]2cc(-c3ccccn3)[n-]n2)CC1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[Cl-] | environment | Tc | null | 18 | scheme 15 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C28 | null | C1N2CN3CN1CP(C2)C3.C1N2CN3CN1CP(C2)C3.[C-]#[O+].[C-]#[O+].[C-]#[O+].[Cl-] | environment | Tc | null | 18 | scheme 16 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C29 | N4IPA | NC(C[N+]1=CNC([N+](=O)[O-])C1)=N[O-].NC(C[N+]1=CNC([N+](=O)[O-])C1)=N[O-].[O-2] | environment | Tc | null | 19 | scheme 17 | 1 | title | null | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.